Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:10 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 4,220 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Terminated Phase 3 Interventional Results available

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
93
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Nov 1, 2026, 2:10 AM EST
Not listed Not applicable Interventional

Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain

NCT01905137
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Intervention-Botulinum Toxin Type A, placebo
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Nov 1, 2026, 2:10 AM EST
Withdrawn Phase 2 Interventional

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

NCT02460081
View directory record Official record
Conditions
Diabetic Foot, Peripheral Arterial Disease
Interventions
PDA-002, Placebo
Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04767529
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

NCT06602531
View directory record Official record
Conditions
Influenza, Human
Interventions
ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine
Biological · Other
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

NCT00407030
View directory record Official record
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 2 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

NCT01375777
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 1, 2026, 2:10 AM EST
Not listed Phase 4 Interventional

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

NCT04306081
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Nov 1, 2026, 2:10 AM EST
Recruiting Phase 2 Interventional

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07729137
View directory record Official record
Conditions
Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions
150K cells, 500K cells, Placebo
Biological · Procedure
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Torrance, California • Largo, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

NCT02576275
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
Interventions
Duvelisib, Placebo, Rituximab, Bendamustine
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Plainville, Connecticut • Plantation, Florida • Thomasville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

NCT00264537
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo injections, Placebo capsules, Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 4 Interventional Results available

Novel Combination Therapy for Osteoporosis in Men

NCT03994172
View directory record Official record
Conditions
Male Osteoporosis
Interventions
Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Recruiting Phase 2 Interventional

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

NCT07646587
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
WIN378, Placebo
Drug
Lead sponsor
Windward Bio
Industry
Eligibility
40 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Jacksonville, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Recruiting Phase 3 Interventional

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

NCT01974206
View directory record Official record
Conditions
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions
ASP0113, Placebo
Biological · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Nov 1, 2026, 2:10 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obexelimab, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
32
States / cities
Peoria, Arizona • Fresno, California • Huntington Park, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Nov 1, 2026, 2:10 AM EST
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 1, 2026, 2:10 AM EST
Terminated Phase 4 Interventional Results available

Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

NCT04862234
View directory record Official record
Conditions
Hyperglycemia Stress
Interventions
Dulaglutide, Placebo, Continuous glucose monitor (CGM), blinded
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Nov 1, 2026, 2:10 AM EST
Withdrawn Phase 1 Interventional

REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts

NCT01496209
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Chronic Ischemic Cardiomyopathy
Interventions
Endomyocardial injections of allogeneic Human CSps, Endomyocardial injections of vehicle only.
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Nov 1, 2026, 2:10 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Pediatric Patients

NCT01380834
View directory record Official record
Conditions
Pain, Postoperative
Interventions
control group, treatment group
Drug
Lead sponsor
Mihaela Visoiu
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 1, 2026, 2:10 AM EST
Terminated Not applicable Interventional

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

NCT06846593
View directory record Official record
Conditions
ECRB Tendinopathy
Interventions
Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections
Device · Other
Lead sponsor
INCREDIWEAR HOLDINGS, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 1, 2026, 2:10 AM EST